AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 121 min read$ALHC

KAO JOHN E sold $4.9M of ALHC

KAO JOHN E (Chief Executive Officer) sold 385,270 shares of Alignment Healthcare, Inc. (ALHC) at $12.68 ($4.89M total) on 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Sep 12, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALHC
Bearish
medium confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCBearishMed
01

Why it matters

The sale represents a $4.9M reduction in CEO holdings, which may be interpreted by investors as a bearish sign.

02

Market read

Insider sales are closely watched; this filing could influence short-term price action.

03

What to watch

Pre-arranged 10b5-1 plans are often used for tax planning and may not reflect sentiment.

Relevance 5/10Novelty 7/10Timing: after-market 2026-09-11

Background

Form 4 filing discloses insider transactions required by SEC; provides first public notice of the sale.

Company-level read

Ticker impact

$ALHCBearishMedium confidence
Context

CEO sold 385,270 shares for $4.9M via 10b5-1 plan on 2026-09-11

Expected impact

Potential modest downside pressure in near-term trading.

Evidence & confidence

Large insider sell by CEO, executed under pre-arranged plan, indicates possible liquidity need or valuation concerns.

Market effects

Sector

May affect healthcare services sector sentiment as insider activity is monitored.

Regional

Limited to US markets where ALHC trades.

Global

Low

Counterpoint

What could challenge this read

Insider sale could be routine liquidity event, not a negative signal.

Key entities

  • Officer
    KAO JOHN E

    Chief Executive Officer of Alignment Healthcare, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALHC insider trading history →

Related articles

OCT 12
$ALHCMed

Why Alignment Healthcare (ALHC) Stock Is Up Today

Alignment Healthcare (ALHC) shares rose 8.6% after its subsidiary announced a new Medicare Advantage plan in Los Angeles and Orange counties. Analyst Ryan Langston lowered his price target to $12 but maintained a Buy rating, citing inpatient utilization pressure. The stock had fallen 13.4% the previous day due to a downgrade and regulatory concerns.

financialcontent.com3 min
OCT 10
$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

suaragarut.id4 min
OCT 9
$ALHCHigh

ALHC Stock Slides As Legal, Cost, And Rating Pressures Mount

Alignment Healthcare Inc. (ALHC) stock fell 14.75% on October 9, 2026, amid concerns over Medicare Advantage reimbursement pressures, legal issues, and cost challenges. The company reported $1.34B in revenue and $36.6M in net income for the latest quarter, but negative cash flow raised concerns. CMS's 2027 Star Ratings and a whistleblower's accounting allegations further pressured the stock, with Barclays cutting its price target to $10.

stockstotrade.com3 min